Health
GSK’s Weak Vaccine Sales Eclipse Brighter Annual Forecast
- Drugmaker raises profit guidance for second consecutive time
- Sales of Shingrix shot for shingles fall on US weakness
This article is for subscribers only.
GSK Plc shares fell as weakness in its vaccines business overshadowed the British drugmaker’s raised profit forecast for the year.
The company revised its annual guidance for vaccine sales downward in a statement Wednesday. The shares dropped 1.5% as of 10:42 a.m. in London after rising 6.4% this year through Tuesday’s close.